Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15134687 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL1922084 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL16195604 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL31535515 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL9582248 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Hydrochloric Acid SCHEMBL31535360 | 0.98 | CYP2D6 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL2917918 | 0.89 | CYP2D6 (0.36) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| Trifluoroacetic Acid SCHEMBL13518942 | 0.84 | PKM (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL2921380 | 0.82 | CYP2D6 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6SYK | |
| SCHEMBL2918065 | 0.82 | CHRNB4 (0.34) | SLC6A2SLC6A4SLC6A3CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | SLC6A2 3054/4885SLC6A4 3133/4885SLC6A3 3108/4885 |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SLC6A2 2876/4885SLC6A4 2509/4885SLC6A3 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.